News
Spinout
Clinical trial of inhaled gene therapy for cystic fibrosis
Global biopharmaceutical company Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) and viral vector manufacturing company OXB have announced the start of a Phase I/II trial of a novel gene therapy that could improve outcomes for people with cystic fibrosis.




